With the help of these molecular biomarkers, endocrine therapy such as tamoxifen and targeted therapy such as trastuzumab have been used as first-line options for ER-positive and HER2-positive breast cancer patients, respectively [4, 5]. Here, ESR1 is linked to breast cancer.